Protalix BioTherapeutics, Inc.
2 Snunit Street
Science Park
Carmiel,
21000
Israel - Map
Phone: 972 4 988 9488
Fax: 972 4 988 9489
Web Site: http://www.protalix.com
| Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program. Protalix BioTherapeutics, Inc. has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the companys ProCellEx protein expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license Icons amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. David Aviezer Ph.D., M.B.A., 44
Chief Exec. Officer, Pres, Exec. Director and Chief Exec. Officer of Protalix Ltd |
$
486.00K |
$
0 | Dr. Yoseph Shaaltiel Ph.D., 56
Founder, Exec. VP of R&D |
$
226.00K |
$
0 | Mr. Yossi Maimon C.P.A., 39
Chief Financial Officer, Principal Accounting Officer, VP, Sec. and Treasurer |
$
233.00K |
$
0 | Dr. Einat Brill Almon Ph.D., 49
Sr. VP of Product Devel. |
$
224.00K |
$
0 | Mr. Ophir Shahaf ,
VP of Bus. Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.27% Nasdaq 0.00%
Profile
